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Undiagnosed hepatitis C virus infection in hemodialysis patients: Value
of HCV RNA and liver enzyme levels. At present, routine screening for
hepatitis C virus (HCV) infection is based on the detection of antiviral
antibodies. Underdiagnosis of HCV infection by using HCV antibody
tests, however, still occurs. Additional diagnostic means are provided by
the polymerase chain reaction (PCR). The measurement of aminotrans-
ferases (ASAT and ALAT) has served as an auxiliary, tess specific test.
The present research aimed to design practical and low cost strategies to
diminish underdiagnosis of HCV infection in dialysis patients. With this
purpose in mind, we examined whether aminotransferases values in HCV
antibody-negative patients could be related to undiagnosed HCV infec-
tion, by using HCV RNA testing by PCR as the gold standard. In 112
hemodialysis patients, we found 78 negative and 34 positive for HCV
antibodies. A major finding was that 22 (28.2%) out of the 78 HCV
antibodies-negative patients had positive HCV RNA by PCR. In repeated
samples taken at a six month follow-up from 19 out of these 22 patients,
only one of them was positive for anti-HCV antibodies; moreover, a
positive HCV RNA by PCR was confirmed in 13 (68.5%) of them. Within
the I ICV antibody-negative group, the mean values of ASAT, ALAT and
gammaglutamiltransfcrase were higher (P < 0.001, P < 0.001 and P <
0.02, respectively) in the HCV PCR-positive versus the HCV PCR-
negative patients. No significant differences were found in the liver
enzyme values between the IICV antibody-negative, HCV RNA positive
and the HCV antibody positive, HCV RNA positive individuals. Histo-
logical samples from two HCV RNA positive, HCV antibody-negative
patients disclosed the presence of a mild liver disease. In conclusion, the
present study demonstrates the critical importance of HCV RNA deter-
mination by PCR in hemodialysis patients who have no detectable
circulating antibodies against the HCV. Furthermore, in conditions in
which PCR technology is not readily available, we have established that
the existence of a moderate increase of aminotransferases is a helpful clue
to detect patients with absent HCV antibodies, and might represent an
useful, low cost tool for HCV screening in dialysis patients.
Infection by hepatitis C virus (HCV) is a major complication
among patients undergoing hemodialysis therapy throughout the
world. There is a high prevalence (10 to 50%) and incidence of
new eases (up to 4.6 new cases/100 patients/year) of HCV in
dialysis units [1—8]. The importance of accurately diagnosing
HCV infection extends beyond the global prognosis of each
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individual patient to become the main issue of epidemiological
safety in dialysis units.
The principal screening method for HCV infection is based on
the detection of antiviral antibodies by ELISA/EIA assays [1—8].
Confirmation of these screening results can be done by more
specific, less sensitive antibody assays, namely RIBA 2 or RIBA 3.
The presence of viral RNA can be assessed by the polymerase
chain reaction (PCR); however, PCR is not employed as a routine
procedure due to its high cost and technical complexity. At
present, only a few studies have analyzed the congruence of
dialysis patients testing positive for HCV by using PCR and
antibody-based methods [9, 10]. So far, the reported results
showed a reasonably good correlation, that is, > 75% of a
coincidence between PCR and positive HCV antibodies [9, 11,
12]. However, in several of the recently published series, the
presence of a number of PCR-positivc ELISA-negative patients
has been acknowledged. The prevalence of this pattern oscillates
between 0 and 9.5% of the total HCV antibody-negative patients
[9, 10]. The consequences of this finding are immediate because of
the disturbing possibility of the existence of a considerable degree
of HVC underdiagnosis.
The practical current attitude of most of the physicians taking
care of dialysis patients is to consider any ELISA negative patient
as not infected by HCV. In general, no other clinical data are used
in supporting the diagnosis of chronic HCV-related liver disease,
with the exception of aminotransferases, namely alanine amino-
transferase (ALAT) and aspartate aminotransferase (ASAT).
Aminotransferases have been basically employed as an additional
method in the follow-up of chronic HCV disease and antiviral
treatments [13]. The practical utility of measuring these enzymes
in assessing the severity of the HCV-related illness has neverthe-
less been limited, provided no good correlations have been found
between the persistence of elevated levels of enzymes and the
histological patterns of liver damage [7, 14, 15]. However, in
interpretating these findings it is necessary to consider that
normal values of aminotransferases are lower in dialysis patients
than in the general population [16—18]. Aminotransferase levels
could be higher in the HCV positive compared to the HCV
negative patients as a group, and thus may be potentially useful as
an aid in population screening for HCV infection.
The present study aimed to diminish HCV underdiagnosis in
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dialysis patients. With this purpose, we examined whether amin-
otranferases values in HCV antibody-negative patients could be
related to undiagnosed HCV infection, using HCV RNA by PCR
as the "gold standard" for the detection of infected patients. We
believe that increasing the value of aminotransferases as a marker
of HCV disease is a worthwhile venture, since there is a definite
need for and inexpensive and simple test to select which patients
need to be further tested for HCV RNA, and/or new tests
improving diagnosis accuracy under conditions where PCR deter-
minations are not readily available.
Methods
We retrospectively examined the records from the last 12
months of 112 patients (67 male and 45 female, mean age 57.3
7.8 years) included in a hemodialysis program in three Units
depending of the same University Hospital. Patients were dialyzed
with conventional techniques, on a three to four hour, three times
week schedule. The diagnosis of renal disease was similar to the
current frequency in Spain as a whole, as reported elsewhere [191.
In this population the annual incidence of newly documented
cases of HCV was 1.8 cases/100 patients/year (Caramelo et a!,
unpublished data). A previous selection was made from the total
dialysis population to ensure that all the patients studied were
negative for hepatitis B virus (HBV) surface antigen (HBsAg) and
human immunodeficiency virus (HIV), as determined by routine
immunological methods, and that no patient was taking poten-
tially hepatotoxic drugs or had an increased alcoholic intake.
The presence of antibodies against HCV proteins was examined
by ELISA 2 (HCV antibody ELISA test system; Ortho, Raritan,
NJ, USA), which was the routine screening method in our
Hospital at the time of the study. Anti-HCV antibodies were
tested in samples frozen at —70°C and only thawed immediately
before the assay.
Simultaneously taken samples were further analyzed for the
presence of HCV RNA by PCR, as described [201. In brief, HCV
RNA was extracted from 200 rl of freshly obtained serum by the
cold guanidinium thiocyanate method. Reverse transcription into
complementaty DNA (eDNA), and eDNA amplification was
performed by nested PCR, using primers from the highly con-
served 5' non-coding region. All the PCR determinations were
run in triplicate in different PCR assays to reduce to a minimum
the risk of false positives due to technical causes. Only samples
with three positive determinations were considered to be HCV
RNA positive. The detection limit of our PCR ranged between
102 to i0 copies of the HCV genome per ml of serum, tested
using a serum sample of known HCV-RNA concentration. This
concentration was determined using a commercially available test
(Amplicor Monitor; Roche, Basel Switzerland). Special care was
taken for processing the samples in less than a week, and to avoid
deterioration of the RNA until processing all the samples were
kept at —70°C and thawed only once. To assess the reliability of
both HCV RNA and anti-HCV antibody determinations, as well
as to detect the existence of patients who had HCV antibody-
delayed seroconversion, a second sample was obtained after a
six-month follow-up period in the HCV RNA positive, anti-HCV
negative patients. ELISA 2 and PCR were performed in this
sample as described above. Unfortunately, only 19 patients were
still available for this second round of determinations; one patient
was transfered to another Unit and two died. The laboratory staff
was blinded as to the identity of the patients, and sera from HCV
Table 1. Values of liver enzymes in HCV RNA positive and HCV
RNA negative, HCV antibody-negative patients
ASAT ALAT GGT
HCV RNA positive 21.1 j•3 28.7 2.8 38.1 6.7"
(N = 21)
HCV RNA negative 13.9 0.4 16.0 0.5 21.8 3.1
(N = 56)
a P < 0.001 between groups
"P < 0.02 between groups
RNA negative individuals were used as a control for false
positivity. To further ascertain the actual pathological importance
of the serological findings, after receiving an informed consent
from each patient, liver samples were obtained by percutaneous
biopsy in two HCV antibody-negative, PCR-positive patients who
were potential candidates for living donor kidney transplantation
(patients A and B). In the two biopsied patients, additional
determinations were done of antiHBs and anti-HBV core (anti-
HBc) antibodies. The biopsies were evaluated by a liver patholo-
gist who was blinded to the clinical and biochemical characteris-
tics of the patients. The liver samples were stained with
hematoxylin-eosin, Masson trichrome, Wilder, PAS diastase, or-
ceine and Perls stains. Additional immunohistochemistry tech-
niques were applied to the liver samples for the determination of
HBV surface and core antigens.
Serum biochemistry values, including ALAT, ASAT and gam-
maglutamyltransferase (GGT) were assessed monthly by means of
an autoanalyzer (SMAC2O). The mean SEM value of the 12
months before sampling for the HCV RNA and anti-HCV
antibodies, and the existence of peaks of each enzyme activity
were recorded. As a method for classifying the patients, we
conventionally defined an increased value of ALAT as the mean
level of enzymatic activity equal to or higher than the mean 2
SDs in this population, that is, 24 U/liter.
Statistics
Results are expressed as mean SEal. The chi square test with
a Yates correction was used to determine the statistical differ-
ences between data entered in 2 X 2 contingency tables. The
unpaired Student's t-test was used to evaluate the differences
between normally distributed, continuous variables. A value of
P < 0.05 (two-tailed) was considered significant.
Positive and negative PCR diagnoses were considered to be the
true positive and true negative values for the calculation of
sensitivity and specificity. Sensitivity and specificity were calcu-
lated by conventional formulae.
Results
Seventy-eight patients tested negative and 34 patients tested
positive for HCV infection by ELISA II. In the first round of
determinations, 22 (28.2%) out of 78 HCV antibody-negative
patients had a positive HCV RNA by PCR. One patient who
tested positive for anti-HCV antibodies in the second round of
determinations was discarded in doing the final calculations (see
below). Within this group, the mean values of ASAT, ALAT and
GGT were significantly higher in the HCV PCR-positive com-
pared with the HCV PCR-negative group (Table 1). As a com-
parison, the mean values of ASAT, ALAT and GGT in the 34
HCV antibody-positive patients were 25.1 9.3, 36.2 10.4 and
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HCV RNA positive 17
HCV RNA negative 3
38,1 5.6, respectively (P = NS with respect to the HCV RNA
positive, HCV antibody-negative patients). Only four (11.7%) out
of these 34 HCV positive patients tested negative by HCV PCR.
As shown in Table 2, 85% of the anti-HCV antibody-negative
patients with ALAT values higher than 24 U/liter were positive by
PCR. However, only 7% of the individuals of this group with
ALAT < 24 U/liter were positive for HCV RNA (P < 0.001
between groups).
Based on these values, the diagnostic sensitivity and specificity
of anti-HCV antibodies were 62.5% and 72.7%, respectively. On
the other hand, the sensitivity of the increase in ASAT equal or
above a mean value of 24 U/liter as a marker of HCV infection
was 80.9%. Relevant data appeared in the follow-up determina-
tions performed at six months from the first sampling. Only one
out of 19 patients seroconverted to HCV positive antibodies. In 6
(31.5%) patients, HCV RNA by PCR became negative in the
second sample, whereas it remained positive in 13 individuals
(68.5%). No positive testing of HCV RNA was found in the
control sera. As mentioned above, the only patient who seroeon-
verted the anti-HCV antibodies in the second round of determi-
nations was omitted in the final calculations of the anti-HCV
negative group. The six patients who had negative HCV RNA in
the second determination were not, however, excluded in the
calculations of liver enzyme values, since new determinations at
longer follow-up periods will be needed to accurately determine
whether the HCV RNA becomes definitively negative.
The liver biopsies of the two PCR positive patients showed the
following abnormalities: the first patient (patient A) had hepato-
cyte hyperplasia, with increased lipofusein accumulation and some
Councilman bodies. Portal spaces had mild increase of fibrotic
tissue and duetular proliferation, and one extense fibrous tract
was evident. The second patient (patient B) had signs of hepato-
cyte hyperplasia, mild steatosis and a moderate increase in portal
cellularity. Oreeine staining was negative and no changes of acute
hepatitis were observed in any of the two eases. Even though the
histological patterns of these two patients were definitely abnor-
mal, we classified them as nonspecific, since no signs of present
inflammatory activity were detected. To further establish the
specificity of the biopsy findings for HCV infection, several
serological markers of HBV were examined in patients A and B.
The results showed the patients to be negative for A antiHBs and
antiHBe, and positive for B antiHBs and antiHBe. HBV surface
and core antigens were nevertheless negative in the liver biopsies.
Discussion
The present study demonstrates the existence of a high propor-
tion of HCV RNA positive patients who would be diagnosed as
HCV negative according to their HCV antibodies. The perfor-
mance of a second round of HCV RNA and anti-HCV antibody
determinations demonstrates that the high frequency of positive
testing for HCV RNA in anti-HCV antibody-negative patients
was neither artifaetual nor due to a delay in finding positive
antibodies. Nordenfelt et al have recently confirmed that positive
testing for HCV RNA might precede the appearance of anti-HCV
antibodies [21]. This was, however, not the ease in our patients,
with the exception of only one. In this regard, the follow-up period
of six months is sufficient to consider that the anti-HCV negative,
HCV RNA-positive patients can be classified as individuals who
did not form antibodies against the proteins included in the
ELISA assay. The fact that 6 out of 19 patients who were HCV
RNA positive became negative in the second determination did
not necessarily mean that the first determination was a false
positive, since spontaneous changes in HCV viremia are not
infrequent. Long-term follow-up studies will clarify this issue in
the future. A main finding in our study was that small but
consistent abnormalities in plasma aminotransferases, in the
particular setting of dialysis patients, may be instrumental for the
detection of liver infection in patients negative for routine anti-
HCV antibody determinations. Furthermore, the present data
confirm that a negative ELISA II is an insufficient eriterium to
rule out the presence of HCV infection [10, 22], and this study
conveys the message that a subgroup of HCV antibody-negative
patients exists who are actually carriers of HCV hepatitis. The
recent appearance of more advanced serological tests for the
detection of HCV antibodies might improve the efficacy of these
assays and, therefore, reduce the number of undiagnosed patients.
This issue needs to be addressed in future studies.
The present findings advise performing HCV PCR in those
patients with aminotransferases higher than normal for the dial-
ysis population. However, actual alterations of liver enzymes may
remain unnoticed if the same normality scale as for the general
population is used for dialysis patients. The lower values of
aminotransferases in dialysis patients would also potentially help
to explain why some authors have found neither enough sensitivity
nor specificity of these enzymes in the diagnosis of dialysis-related
HCV disease, as well as the lack of correlation between the
increase of aminotransferases and liver pathology in dialysis
patients reported by several groups [7, 13, 14]. These investigators
only considered values higher than 1.5 to 2 times the maximum of
normality of nondialysis individuals to be elevated in dialysis
patients. A recent communication by Guh et al provides further
support for the need to reduce the level of aminotransferases
considered abnormal in dialysis patients [23]. In the present study,
even in the ease of HCV antibody-positive patients, aminotrans-
ferase values were mostly within the normal range for a nonure-
mic population and were indeed lower than those found in a
nondialysis HCV-positive population [24].
The existence of a significant amount of undiagnosed HCV
infection by the antibody-based method is most probably related
to a decreased anti-HCV immunological reactivity in dialysis
patients. Although a very late (more than 6 months) seroeonver-
sion cannot be completely ruled out, it is a rare enough condition
to not influence our findings.
We have recently found that a group of dialysis patients with
positive plasma HBV DNA exists, in the absence of either antiHbs
or antiHbe antibodies. On the contrary, in a population of
non-dialysis controls who had a prior HBV infection, a positive
HBV DNA was always associated with the presence of HBe [25].
The percentage of HCV antibody negative, HCV PCR positive
patients found in the present study is higher than those reported
by other groups [9, 12, 22, 24—26], but in a similar range as that
found by others [10, 27—291. The differences observed between
Table 2. Negative and positive HCV RNA according to ALAT values
among patients with negative anti-HCV antibodies
ALAT  24 U/liter ALAT < 24 U/liter
4
53
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groups may be due to the sample processing method. Unfortu-
nately, no historical samples were available to check whether
anti-HCV antibodies were positive sometime earlier to the first
analysis done in our Units.
The histological data demostrated that liver disease was present
in the two patients who underwent a biopsy. Their histological
pattern was indicative of a mild degree of injury, and no data of
evolution to chronic hepatitis were present. Furthermore, no
evidence existed in either case to consider the possibility of a liver
diseare other than HCV hepatitis. Therefore, the hypothesis can
be raised that the absence of present inflammation may be related
to the lack of sufficient stimulation of the immunological mecha-
nisms, and subsequently of the formation of the antibodies that
react in ELISA II. A greater number of histology samples is
certainly necessary for testing the validity of this hypothesis. in
this regard, the recent data of Al Meshari Ct al support the
hypothesis that benign histological patterns may be frequent in
the patients who test positive for HCV RNA but negative for
HCV antibodies [10]. In contrast, severe histological patterns are
the most frequent finding in HCV antibody-positive patients [7,
10].
Finally, the question should be posed as to whether the HCV
RNA positive, anti-HCV antibody-negative patients are HCV
carriers for epidemiological safety purposes. In our study, the
relationship of positive PCR with alterations in aminotransferases
and liver biopsies suggested that a degree of hepatic disease really
existed. Accordingly, we considered a positive PCR as a definite
criteria of the presence of a HCV-related illness.
In terms of cost-benefit relationships, the present study's main
application may be in orientating the selection of those HCV
antibody-negative patients who are more prone to test positive for
HCV-RNA by PCR. Therefore, it may facilitate the goal of a
complete detection of all the HCV infected patients without
performing HCV-RNA determinations to all the individuals
undergoing dialytic therapy. in addition, the present data advo-
cate for decreasing the threshold value of aminotransferases that
are currently considered to be abnormally elevated in dialysis
patients. In doing so, sensitivity in using aminotransferases as a
marker of liver injury will be enhanced without a major decrease
in specificity.
Long-term follow-up studies are necessary to address the
impact of using a mild increase in aminotransferases as a practical
marker for the presence of HCV-related liver disease in large
HCV antibody-negative populations.
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